XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on September 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center

Molecular Cancer Therapeutics

Volumn 8, Issue 5, 2009, Pages 992-999

  Muggia, Franco M ^a   Peters, Godefridus J ^b   Landolph Jr , Joseph R ^c  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; BREAST CANCER RESISTANCE PROTEIN; CETUXIMAB; DASATINIB; DIHYDROFOLATE REDUCTASE; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA METHYLTRANSFERASE; ERLOTINIB; FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; I KAPPA B KINASE; IMATINIB; INTERLEUKIN 12; K RAS PROTEIN; LAPATINIB; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXALIPLATIN; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SORAFENIB; SUNITINIB; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; TRASTUZUMAB; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RESEARCH; CANCER RISK; CARCINOGENESIS; CONFERENCE PAPER; DNA SYNTHESIS; DRUG RESEARCH; DRUG TARGETING; ENVIRONMENTAL FACTOR; EPIGENETICS; GENOMICS; HISTORY OF MEDICINE; HUMAN; LIVER METASTASIS; MALIGNANT NEOPLASTIC DISEASE; ONCOGENE; POSTGRADUATE EDUCATION; PRIORITY JOURNAL; RNA SYNTHESIS; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; FLUOROURACIL; HUMANS; NEOPLASMS;

EID: 66849099602     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0731     Document Type: Conference Paper

References (56)

1. Rutman RJ, Cantarow A, Paschkis KE. The catabolism of uracil in vivo and in vitro. J Biol Chem 1954;210:321-329 PubMed.
2. Heidelberger C, Leibman KC, Harbers E, Bhargava PM. The comparative utilization of uracil-2-C14 byliver, intestinal mucosa, and Flexner-Jobling carcinoma in the rat. Cancer Res 1957;17:399-404. PubMed.
3. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957;179:663-666 PubMed doi:10.1038/179663a0.
4. Curreri AR, Ansfield FJ, McIver FA, Waisman HA, Heidelberger C. Clinical studies with 5-fluorouracil. Cancer Res 1958;18:478-484 PubMed.
5. Chaudhuri NK, Montag BJ, Heidelberger C. Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2-C14 and 5-fluoroorotic- 2-C14 acid in vivo. Cancer Res 1958;18:318-328 PubMed.
6. Harbers E, Chaudhuri NK, Heidelberger C. Studies on fluorinated pyrimidines. VIII. Further biochemical and metabolic investigations. J Biol Chem 1959;234:1255-1262 PubMed.
7. Mukherjee KL, Heidelberger C. Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14. J Biol Chem 1960;235:433-437 PubMed.
8. Reichard P, Skold O, Klein G, Revesz L, Magnusson PH. Studies on resistance against 5-fluorouracil. I. Enzymes of the uracil pathway during development of resistance. Cancer Res 1962;22:235-243 PubMed.
9. Reyes P, Hall TC. Synthesis of 5-fluorouridine 5′-phosphate bya pyrimidine phosphoribosyltransferase of mammalian origin. II. Correlation between the tumor levels of the enzyme and the 5-fluorouracil-promoted increase in survival of tumor-bearing mice. Biochem Pharmacol 1969;18:2587-90. PubMed doi:10.1016/0006-2952(69)90378-90385
10. Cohen SS, Flaks JG, Barner HD, Loeb MR, Lichtenstein J. The mode of action of 5-fluorouracil and its derivatives. Proc Natl Acad Sci U S A 1958;44:1004-1012 PubMed doi:10.1073/pnas.44.10.1004.
11. Hartmann KU, Heidelberger C. Studies on fluorinated pyrimidines. XIII. Inhibition of thymidylate synthetase. J Biol Chem 1961;236:3006-3013 PubMed.
12. Heidelberger C, Kaldor G, Mukherjee KL, Danneberg PB. Studies on fluorinated pyrimidines. XI. In vitro studies on tumor resistance. Cancer Res 1960;20:903-909 PubMed.
13. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracilsensitive and-resistant murine colon adenocarcinomas. Cancer Res 1982;42:450-456 PubMed.
14. Spears CP, Gustavsson BG, Mitchell MS, et al. Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res 1984;44:4144-4150 PubMed. (Pubitemid 14041649)
15. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ. Fluorouracil and high-dose leucovorin in previouslytreated patients with metastatic breast cancer. J Clin Oncol 1989;7:890-899 PubMed. (Pubitemid 19172462)
16. Peters GJ, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, Pinedo HM. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994;12:2035-2042 PubMed. (Pubitemid 24356018)
17. Johnston PG, Fisher ER, Rockette HE, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-2647 PubMed. (Pubitemid 24379651)
18. Horikoshi T, Danenberg KD, Stadlbauer TH, et al. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res 1992;52:108-116 PubMed.
19. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322-1327 PubMed. (Pubitemid 30226214)
20. Smorenburg CH, Peters GJ, van Groeningen CJ, et al. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluorouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann Oncol 2006;17:35-42. PubMed doi:10.1093/annonc/mdj046. (Pubitemid 43033837)
21. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapyalone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059-2069 PubMed doi:10.1200/JCO.2003.11.126. (Pubitemid 46606353)
22. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000;355:1041-7. PubMed doi:10.1016/S0140-6736(00)02034-2041 (Pubitemid 30162806)
23. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342 PubMed doi:10.1056/NEJMoa032691. (Pubitemid 38702844)
24. Sledge GW, Jr. What is targeted therapy? J Clin Oncol 2005;23:1614-1615 PubMed doi:10.1200/JCO.2005.01.016.
25. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004;22:529-536 PubMed doi:10.1200/JCO.2004.05.064. (Pubitemid 41079782)
26. Van Triest B, Peters GJ. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology 1999;57:179-194 PubMed doi:10.1159/000012030. (Pubitemid 29481691)
27. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995;20:191-197 PubMed.
28. Ju J, Pedersen-Lane J, Maley F, Chu E. Regulation of p53 expression by thymidylate synthase. Proc Natl Acad Sci U S A 1999;96:3769-3774 PubMed doi:10.1073/pnas.96.7.3769. (Pubitemid 29168985)
29. Giovannetti E, Backus HH, Wouters D, et al. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer 2007;96:769-775 PubMed doi:10.1038/sj.bjc.6603639. (Pubitemid 46376640)
30. Mauritz R, Peters GJ. Pharmacogenetics of colon cancer and potential implications for 5-fluorouracil-based chemotherapy. Current Pharmacogenomics 2006;4:57-67. doi:10.2174/157016006776055419.
31. Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiencyin patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 2001;41:151-7. PubMed doi:10.1016/S0065- 2571(00)00011-X. (Pubitemid 32520320)
32. Mattison LK, Soong R, Diasio RB. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 2002;3:485-492 PubMed doi:10.1517/14622416.3.4.485. (Pubitemid 34814677)
33. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939-950 PubMed doi:10.1016/j.ejca.2003.12.004. (Pubitemid 38496249)
34. Feng Z, Hu W, Hu Y, Tang MS. Acrolein is a major cigarette-related lung cancer agent: preferential binding at p53 mutational hotspots and inhibition of DNA repair. Proc Natl Acad Sci U S A 2006;103:15404-15409 PubMed doi:10.1073/pnas.0607031103. (Pubitemid 44625604)
35. Cavalieri E, Chakravarti D, Guttenplan J, et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 2006;1766:63-78. PubMed.
36. Ding S, Shapiro R, Geacintov NE, Broyde S. 4-hydroxyequilenin-adenine lesions in DNA duplexes: stereochemistry, damage site, and structure. Biochemistry2 007;46:182-191 PubMed doi:10.1021/bi061652o. (Pubitemid 46075022)
37. Shreeram S, Hee WK, Demidov ON, et al. Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. J Exp Med 2006;203:2793-2799 PubMed doi:10.1084/jem.20061563. (Pubitemid 46026157)
38. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007;121:2373-2380 PubMed doi:10.1002/ijc.23173. (Pubitemid 350022405)
39. Phillips M, Altorki N, Austin JH, et al. Detection of lung cancer using weighted digital analysis of breath biomarkers. Clin Chim Acta 2008;393:76-84. PubMed doi:10.1016/j.cca.2008.02.021.
40. Affara NI, Trempus CS, Schanbacher BL, et al. Activation of Akt and mTOR in CD34+/K15+ keratinocyte stem cells and skin tumors during multi-stage mouse skin carcinogenesis. Anticancer Res 2006;26:2805-2820 PubMed. (Pubitemid 44161767)
41. Chodankar R, Kwang S, Sangiorgi F, et al. Cell-nonautonomous inductor of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Curr Biol 2005;15:561-565 PubMed doi:10.1016/j.cub. 2005.01.052. (Pubitemid 40413396)
42. Zhao Y, Glesne D, Huberman E. A human peripheral blood monocyte-derived subset acts as pluripotent stem cells. Proc Natl Acad Sci U S A 2003;100:2426-2431 PubMed doi:10.1073/pnas.0536882100. (Pubitemid 36297515)
43. Yang Y, Bai J, Shen R, et al. Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hyponiem-inducible factor-1 a under hypoxic conditions. Cancer Res 2008;68:4077-85. PubMed doi:10.1158/0008-5472. CAN-07-6182.
44. King TJ, Fukushima LH, Hieber AD, Shimabukuro KA, Sakr WA, Bertram JS. Reduced levels of connexin43 in cervical dysplasie: inducible expression in a cervical carcinoma cell line decreases neoplastic potential with implications for tumor progression. Carcinogenesis 2000;21:1097-1109 PubMed doi:10.1093/carcin/21.6.1097. (Pubitemid 30389333)
45. Ramirez-Valle F, Braunstein S, Zavadil J, Formenti SC, Schneider RJ. E1F4Gl links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J Cell Biol 2008;181:293-307. PubMed doi:10.1083/jcb.200710215.
46. Clemens F, Verma R, Ramnath J, Landolph JR. Amplification of the Ect2 proto-oncogene and over-expression of Ect2 mRNA and protein in nickel compound and methylcholanthrene-transformed 10T1/2 mouse fibroblast cell lines. Toxicol Appl Pharmacol 2005;206:138-149 PubMed doi:10.1016/j.taap.2005.02.009. (Pubitemid 40834308)
47. Ke Q, Li Q, Ellen TP, Sun H, Costa M. Nickel compounds induce phosphorylation of histone H3 at serine 10 by activating JNK-MAPK pathway. Carcinogenesis 2008;29:1276-1281 PubMed doi:10.1093/carcin/bgn084.
48. Peterson EJ, Bögler O, Taylor SM. p53-mediated repression of DNA methyltransferase 1 expression by specific DNA binding. Cancer Res 2003;63:6579-6582 PubMed. (Pubitemid 37322935)
49. Daikoku T, Tranguch S, Trofimova IN, et al. Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res 2006;66:2527-31. PubMed doi:10.1158/0008-5472.CAN-05- 4063.
50. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci U S A 2006;103:11154-11159 PubMed doi:10.1073/pnas.0603672103. (Pubitemid 44156488)
51. Liu M, Hummer BT, Li X, Hassel BA. Camptothecin induces the ubiquitin-like protein, ISG15, and nuances ISG15 conjugation in response to interferon. J Interferon Cytokine Res 2004;24:647-654 PubMed.
52. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody(SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:1190-1197 PubMed doi:10.1002/pbc.21450.
53. Koehler SE, Ladner RD. Small interfering RNA-mediated suppression of dUTPase sensitizes cancer cell lines to thymidylate synthase inhibition. Mol Pharmacol 2004;66:620-626 PubMed. (Pubitemid 39329261)
54. Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, Goldman ID. The proton-coupled folate transporter: impact on penetrated transport and on antifolates activities as compared to the reduced folate carrier. Mol Pharmacol 2008;74:854-862
55. Gibbs DD, Theti DS, Wood N, et al. BGC 945, a novel tumor-sensitive thymidylate synthase initiator targeted to α-folate receptor- overexpressing tumors. Cancer Res 2005;65:11721-8. PubMed doi:10.1158/0008-5472. CAN-05-2034.
56. Racanelli AC, Turner FB, Xie LY, Taylor SM, Moran RG. A mouse gene that coordinates epigenetic controls and transcriptional interference to achieve tissue-specific expression. Mol Cell Biol 2008;28:836-848 PubMed doi:10.1128/MCB.01088-07.